Literature DB >> 17234674

The predictive value of medical history taking and Chlamydia IgG ELISA antibody testing (CAT) in the selection of subfertile women for diagnostic laparoscopy: a clinical prediction model approach.

S F P J Coppus1, B C Opmeer, S Logan, F van der Veen, S Bhattacharya, B W J Mol.   

Abstract

BACKGROUND: Medical history taking as well as Chlamydia antibody titre (CAT) testing are currently used in the selection of patients for diagnostic laparoscopy with tubal patency testing. Most research has focused on the predictive value of CAT in isolation from medical history. We assessed therefore whether the combination of medical history and CAT improves the efficiency of selecting patients for laparoscopy as compared to the use of either medical history or CAT.
METHODS: Data of 207 consecutive subfertile women were used to create multivariable logistic regression models for the prediction of tubal disease as diagnosed by diagnostic laparoscopy.
RESULTS: The model with data of medical history only had an area under the receiver operating characteristic curve (AUC) of 0.65 (95% CI 0.56-0.74). Addition of CAT increased the AUC to 0.70 (95% CI 0.62-0.78) (P = 0.065). CAT was positive in 40 women and showed a sensitivity of 0.37 (95% CI 0.26-0.49) for a specificity of 0.88 (95% CI 0.82-0.93). In CAT positive women, a blank medical history did not decrease the probability of tubal disease. Of the 167 women tested CAT negative, 23 (14%) still had a high probability of disease due to their medical history and 11 of them (48%) showed tubal abnormalities on diagnostic laparoscopy.
CONCLUSIONS: CAT testing adds valuable information to a woman's risk profile based on her medical history. The combination of medical history taking and CAT testing has a better yield for diagnosing tubal disease than either of these alone.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17234674     DOI: 10.1093/humrep/del521

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  7 in total

Review 1.  Human and Pathogen Factors Associated with Chlamydia trachomatis-Related Infertility in Women.

Authors:  S Menon; P Timms; J A Allan; K Alexander; L Rombauts; P Horner; M Keltz; J Hocking; W M Huston
Journal:  Clin Microbiol Rev       Date:  2015-10       Impact factor: 26.132

2.  Impact of Chlamydia trachomatis in the reproductive setting: British Fertility Society Guidelines for practice.

Authors:  Valentine Akande; Cathy Turner; Paddy Horner; Andrew Horne; Allan Pacey
Journal:  Hum Fertil (Camb)       Date:  2010-09       Impact factor: 2.767

3.  Chlamydia trachomatis immunoglobulin G3 seropositivity is a predictor of reproductive outcomes in infertile women with patent fallopian tubes.

Authors:  Anne Z Steiner; Michael P Diamond; Richard S Legro; William D Schlaff; Kurt T Barnhart; Peter R Casson; Gregory M Christman; Ruben Alvero; Karl R Hansen; William M Geisler; Tracey Thomas; Nanette Santoro; Heping Zhang; Esther Eisenberg
Journal:  Fertil Steril       Date:  2015-09-25       Impact factor: 7.329

4.  Sero-epidemiological assessment of Chlamydia trachomatis infection and sub-fertility in Samoan women.

Authors:  S Menon; S H Stansfield; M Walsh; E Hope; L Isaia; A A Righarts; T Niupulusu; S V A Temese; L Iosefa-Siitia; L Auvaa; S A Tapelu; M F Motu; T Suaalii-Sauni; P Timms; P C Hill; W M Huston
Journal:  BMC Infect Dis       Date:  2016-04-21       Impact factor: 3.090

Review 5.  Diagnostic laparoscopy for unexplained subfertility: a comprehensive review.

Authors:  Wissam Arab
Journal:  JBRA Assist Reprod       Date:  2022-01-17

6.  A concise infertility work-up results in fewer pregnancies.

Authors:  J A M Hamilton; J W van der Steeg; C J C M Hamilton; J P de Bruin
Journal:  Hum Reprod Open       Date:  2021-08-20

7.  Chlamydia antibody testing helps in identifying females with possible tubal factor infertility.

Authors:  Swapnil Singh; Shilpa Bhandari; Pallavi Agarwal; Priya Chittawar; Ratna Thakur
Journal:  Int J Reprod Biomed       Date:  2016-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.